Secondary prevention of cervical cancer

Basu, Partha; Mittal, Srabani; Vale, Diama Bhadra; Kharaji, Youssef Chami

doi:10.1016/j.bpobgyn.2017.08.012

Cited by 82 publications

(90 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The Attitude Scale for Early Diagnosis of Cervical Cancer Scale (ATEDCCS) was developed by Özmen and Özsoy in 2009. The scale is comprised of four subscales: Susceptibility (8,9,12,14,15,19,21,24,28), Severity (1,2,5,7,10,18,26,29), Barriers (11,13,17,20,23,25,30) and Benefits (3,4,6,16,22,27). The Cronbach's Alpha coefficient is between 0.89 and 0.70 for the entire scale and its subscales.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Kadınların serviks kanserinin erken tanısına yönelik tutumları:sağlık sorumluluğu ve ilişkili faktörler

Önal

Yılmaz

2020

Cukurova Medical Journal

View full text Add to dashboard Cite

show abstract

Section: Methodsmentioning

confidence: 99%

“…Early diagnosis has a key role in the treatment of cervical cancer [4][5] . Knowledge of significant risk factors causing this disease and regular cytological screening sessions increase the survival rates 6 .…”

Section: Introductionmentioning

confidence: 99%

Kadınların serviks kanserinin erken tanısına yönelik tutumları:sağlık sorumluluğu ve ilişkili faktörler

Önal

Yılmaz

2020

Cukurova Medical Journal

View full text Add to dashboard Cite

show abstract

“…The occurrence of false-negative and unsatisfactory cytology tests prompted the development of new technologies that improve screening quality. 4 In addition, the evidence of a causal relationship between oncogenic HPV infection and cervical cancer and its precursor lesions led to the development of HPV-DNA detection techniques to prevent and identify these lesions. 5 There is currently scientific evidence supporting HPV-DNA tests as the primary screening method for women aged 30 years or older.…”

Section: Methodsmentioning

confidence: 99%

Guidelines for HPV-DNA Testing for Cervical Cancer Screening in Brazil

Zeferino

Bastos

Vale

et al. 2018

Rev Bras Ginecol Obstet

View full text Add to dashboard Cite

Evidence-based clinical guidelines ensure best practice protocols are available in health care. There is a widespread use of human papillomavirus deoxyribonucleic acid (HPV-DNA) tests in Brazil, regardless of the lack of official guidelines. On behalf of the Brazilian Association for the Lower Genital Tract Pathology and Colposcopy (ABPTGIC, in the Portuguese acronym), a team of reviewers searched for published evidence and developed a set of recommendations for the use of HPV-DNA tests in cervical cancer screening in Brazil. The product of this process was debated and consensus was sought by the participants. One concern of the authors was the inclusion of these tests in the assessment of women with cytologic atypia and women treated for cervical intraepithelial neoplasia (CIN). Testing for HPV is recommended in an organized screening scenario to identify women with precursor lesions or asymptomatic cervical cancer older than 30 years of age, and it can be performed every 5 years. It also has value after the cytology showing atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesions (LSILs) as a triage test for colposcopy, in the investigation of other cytological alterations when no abnormal findings are observed at colposcopy, seeking to exclude disease, or, further, after treatment of high-grade cervical intraepithelial neoplasia, to rule out residual disease.

show abstract

“…In contrast, patients that are accurately diagnosed at an earlier stage or with precancerous diseases have a 5-year survival rate of 90%. Poor survival is primarily due to uncontrolled lymph node metastasis, which means that curative surgery is not a viable option for more than 50% of patients at the time of diagnosis [5][6]. Therefore, investigating the pathogenesis of CC to identify novel biomarkers is crucial.…”

Section: Introductionmentioning

confidence: 99%

Overexpression of GNB2L1 is associated with poor prognosis in cervical cancer patients

Qi¹,

Xu²,

Tuerxun³

et al. 2019

Preprint

View full text Add to dashboard Cite

Background: Among women, cervical cancer (CC) is the fourth most prevalent cancer worldwide. Multiple bio-makers have been identified for tumor diagnosis and prognosis. However, no single bio-maker for CC detection exists that is both highly sensitive and specific. In this report, we explored the role of guanine nucleotide-binding protein subunit beta-2-like 1 (GNB2L1) in CC progression in Uyghur women. Methods: In the present study, 132 patients with cervical squamous cell carcinoma (CSCC), 56 cases with cervical intraepithelial neoplasia (CIN) were enrolled. GNB2L1 mRNA and protein expression levels were analyzed in CSCC, CIN, and normal cervical (NC) tissues and in CC cell lines using qRT-PCR, western blot, and immunohistochemistry. Stable GNB2L1-knockdown CC cells (shGNB2L1) were also created and lipid accumulation was measured with Oil Red O staining. Additionally, changes in GNB2L1 gene copy number were investigated with qRT-PCR and sequencing. A gene regulatory network was constructed using the STRING database. Finally, patient survival was assessed with Kaplan‑Meier and log-rank tests. Results: Our results indicated that GNB2L1 mRNA and protein are overexpressed in CSCC tumor tissues when compared to CIN and NC tissues. GNB2L1 expression was associated with the degree of cell differentiation (P = 0.001), lymph node metastasis (P = 0.049), and the clinical stage (P = 0.017). Oil Red O staining showed that lipid levels were lower in shGNB2L1 cells, and that GNB2L1 DNA copy number in CC tissues (29,7200 ± 9,815.061) was significantly higher when compared to NC tissues (19,5100 ± 5,676.392 [T=-2.770, P = 0.009]). Furthermore, patients with CSCC and high GNB2L1 expression demonstrated shorter overall survival times when compared to patients with low GNB2L1 expression (P = 0.002). Multivariate analysis indicated that GNB2L1 overexpression is an independent prognostic factor in patients with CSCC. Conclusions: Overexpression of GNB2L1 may contribute to tumor progression; therefore, it is a potential prognostic biomarker for CSCC patients.

show abstract

Secondary prevention of cervical cancer

Cited by 82 publications

References 56 publications

Kadınların serviks kanserinin erken tanısına yönelik tutumları:sağlık sorumluluğu ve ilişkili faktörler

Kadınların serviks kanserinin erken tanısına yönelik tutumları:sağlık sorumluluğu ve ilişkili faktörler

Guidelines for HPV-DNA Testing for Cervical Cancer Screening in Brazil

Overexpression of GNB2L1 is associated with poor prognosis in cervical cancer patients

Contact Info

Product

Resources

About